Many toxicological test methods, including assays of cell viability and function, require an evaluation of concentration-response data. This often involves curve fitting, and the resulting mathematical functions are then used to determine the concentration at which a certain deviation from the control value occurs (e.g., a decrease of cell viability by 15%). Such a threshold is called the benchmark response (BMR). For a toxicological test, it is often of interest to determine the concentration of test compound at which a pre-defined BMR of, e.g., 10, 25 or 50% is reached. The concentration at which the modelled curve crosses the BMR is called the benchmark concentration (BMC). We present a user-friendly, web-based tool (BMCeasy), designed for operators without programming skills and profound statistical background, to determine BMCs and their confidence intervals. BMCeasy allows simultaneous analysis of viability plus a functional test endpoint, and it yields absolute BMCs with confidence intervals for any BMR. Besides an explanation of the algorithm underlying BMCeasy, this article also gives multiple examples of data outputs. BMCeasy was used within the EU-ToxRisk project for preparing data packages that were submitted to regulatory authorities, demonstrating the real-life applicability of the tool. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is appropriately cited. sessment in classical toxicological studies. The NOAEL is the highest dose/concentration tested that shows no adverse effect in a particular experiment, while the LOAEL is the lowest dose/ concentration at which an adverse effect was observed. The determination of the NOAEL or LOAEL is straightforward; however, uncertainty of these threshold values is poorly defined, and the data is strongly affected by the study design (e.g., sample size, dose
Abbreviations BMC, benchmark concentration; BMCL, benchmark concentration lower limit; BMCU, benchmark concentration upper limit; BMR, benchmark response; CI, confidence interval; LOAEL, lowest observed adverse effect level; NOAEL, no observed adverse effect level selection and dose spacing) (Crump, 1984; Haber et al., 2018; Kimmel and Gaylor, 1988; Barnes and Dourson, 1988; Dourson et al., 1985) .
To overcome this limitation, the benchmark dose concept was developed. It is broadly used and recommended for animal-based studies (EFSA, 2017; Davis et al., 2011; U.S. EPA, 1995 U.S. EPA, , 2012 , and it has also been adapted to analyze data sets from in vitro tests or so-called new approach methods (NAM). As concentrations are the most common dose metric for cell-based tests (Kisitu et al., 2019) , benchmark concentrations (BMC), rather than benchmark doses, are relevant for new approach methods.
The BMC is the concentration at which a specific, pre-defined change in an assay endpoint occurs, and the pre-defined change is called the benchmark response (BMR) (Crump, 1984) . The application of this concept is most straightforward for situations where the concentration-response behavior is monotonic and a mathematical model can be fitted to the experimental data. The BMC is determined as the concentration at which the modeled curve intersects the pre-defined BMR (Fig. 1 ). For example, in the case of viability as test endpoint, a BMR of 12% would define a reduction of viability from 100% to 88%. The uncertainty of the BMC can be calculated and expressed as the confidence interval (CI). The lower limit of the CI (bench mark concentration lower bound; BMCL) can be considered the highest concentration of a compound that does not affect the assay endpoint with a pre-defined confidence level. In this case, "not affecting the assay endpoint" would be interpreted as being "non-cytotoxic", and the CI would relate to the given BMR. In the example, the BMCL indicates the highest concentration at which one can be 97.5% certain that the viability does not deviate more than 12% (BMR) from that of untreated or negative control cells.
Taking the viability example above, one may conclude that all data above 88% viability mean that there is no cytotoxicity, while all data below the BMR (< 88% viability) indicate cytotoxicity. One could then conclude that all test compound concentrations that are below the BMC are non-cytotoxic (have a viability above the BMR). However, this interpretation does not account for the statistical uncertainty of the BMC, and one cannot be sure that toxicant concentrations at the BMC level are indeed non-cytotoxic. If one wants to have a certain confidence that a concentration is non-cytotoxic, it should be lower than the BMCL. Thus, the BMCL provides a better estimation of non-cytotoxic concentrations than the BMC alone. Knowing this threshold is important for choosing test concentrations for functional assays or for gene expression studies (Krug et al., 2013; Rovida et al., 2014; Nyffeler et al., 2017a,b; Waldmann et al., 2014; Rempel et al., 2015; Shinde et al., 2017; House et al., 2017) . As the BMC method uses the information of the whole dataset, including the data uncertainties (i.e., variability produced by experimental errors and fluctuations of experimental parameters), it is less influenced by concentration spacing than a NOAEL, and it provides an estimate of statistical uncertainty of a point of departure (PoD). It is therefore a preferred method for modern toxicological approaches (Hartung and Leist, 2008; Leist et al., 2010 Leist et al., , 2012 Leist et al., , 2014 , and the concept has been used for a number of algorithms to define non-cytotoxic concentrations (Stadnicka-Michalak et al., 2018; Hsieh et al., 2019; Calderazzo et al., 2019; Behl et al., 2015) . Several software tools have been developed to calculate the BMC (Filer et al., 2017; Slob and Setzer, 2014; Ritz and Streibig, 2005) 1,2 , but applying the BMC concept still requires considerably more mathematical/ statistical and programming skills than the NOAEL/LOAEL approach and can be challenging for experimental biologists.
The ideal tool for an experimental in vitro toxicologist without programming skills and working on low to medium throughput test methods would have the following characteristics: (1) requires neither programming skills nor extensive mathematical and statistical knowledge; (2) handles data from cytotoxicity endpoints as well as from functional endpoints (note that the lower
Fig. 1: The benchmark concentration concept for in vitro toxicology data
An example dataset of concentration-response data of a toxicant is shown. Older curve evaluation strategies use the NOAEL (maximal concentration that has no observable adverse effect) and the LOAEL (lowest concentration that evokes an adverse effect) to define the onset of toxicity. The benchmark concept requires definition of a benchmark response level (BMR). The compound concentration that causes the test endpoint (e.g., viability) to drop to the BMR is called the benchmark concentration (BMC). A two-sided confidence interval (CI) can be calculated for the BMC. The lower limit of the CI is defined as BMCL, the upper limit as BMCU. Concentrations lower than the BMCL are likely to produce effects lower than the BMR with a pre-defined level of confidence (usually 97.5%).
detailed user manual of the BMCeasy graphical user interface 3 and the code 8 are available.
Curve fitting and calculation of BMR data
Data for up to two different endpoints can be uploaded at a time, and any BMR can be specified. For both endpoints, three concentration-response models with slightly different constraints are available to fit the data. The best model is selected automatically by BMCeasy. The outputs are the BMCs, their confidence intervals with lower and upper boundaries (the BMCL and BMCU), the parameters used for curve fitting, and a high-quality graph.
Pre-processing of the data and data input
The program was designed on purpose to require a manual check and pre-processing of data: Initial normalization of raw data, detection of outliers and possible re-normalization of data sets (Krebs et al., 2018) is left to the user and needs to be done prior to data upload in standard laboratory programs such as Graph-Pad or Excel. It is of utmost importance that the user is aware of asymptote of functional endpoint data is often > 0); (3) calculates absolute BMC and BMCL values in a standardized way to allow comparison in inter-laboratory projects or between different assays in a test battery ( Fig. 2) , (4) ensures transparency and reproducibility by creating publication-quality graphical output and providing background on the fitting procedure as well as documenting all parameters of the curve fitted to the concentration-response data. To the best of our knowledge, no such program was easily available, therefore we created BMCeasy 3 , a web-based application fulfilling all these requirements.
BMCeasy was programmed in R 4 (R Core Team, 2019) using the well-established drc package for curve fitting and BMC estimation 5 (Ritz and Streibig, 2005; Ritz, 2010) and the R Shiny package to produce the web interface 6 . The tool is suitable for data obtained from a wide variety of in vitro test methods. It has been used and optimized in practice during collaborative work in the EU-ToxRisk project 7 and several other international collaborative research activities involving laboratories from both academia and industry.
In the present work, we aim to give an overview of the workflow, together with some example applications of the program. A 
Fig. 2: Graphical representation of the absolute versus the relative BMC50
A) The absolute BMC50 is defined independently of the data and their curve fit, the curve's inflection point or its lower asymptote. The absolute BMC50 is thus always defined as a 50% reduction of the respective endpoint, independent of the lower asymptote. B) The relative BMC50 is dependent on the data, in particular on the lower asymptote, because it is defined by the midpoint of the difference between the upper and the lower asymptotes. For a 4-parameter sigmoid fit, this is identical to the curve's inflection point. The lower asymptote is shown in red, the upper asymptote in grey. The dashed vertical line (black) indicates the BMC50. BMCeasy uses the absolute BMC50 definition as in A.
BMC calculation requires datasets with a downward direction (towards 0%) for increasing concentrations of test chemical. For example, a decrease in cell viability or inhibition of cell migration are typical assay responses that can be evaluated. Upward responses (e.g., enhanced cell proliferation, or activation of a reporter gene) cannot be evaluated directly; such datasets need prior transformation (e.g., inversion or mirroring on a line parallel to the x-axis) (Weimer et al., 2012) .
Curve modeling
Concentration-response input data is fitted using the log-logistic function of the drc package. The curve fits differ in their constraints and possible ranges of curve fit variables (Fig. 3A) 9 . The parameters were not derived from and validated by stringent statistical procedures. They rather reflect the experience gained the quality of data necessary to yield reasonable outputs. In some cases, repetitions of an experiment may be necessary to provide data sets of sufficient quality. Sometimes data sets may need to be excluded from analysis (e.g., when a compound used in a viability test makes cells proliferate (reaching values > 100%). As the software performs poorly with low-quality data and requires manual pre-processing, BMCeasy is not suitable for high-throughput data processing.
BMCeasy input datasets are simple lists containing the name of the chemical tested and, in each line, a test concentration, the concentration unit, and the response (normalized to 100% relative to a vehicle control or to another reference point). In case of several replicates, they may be entered as individual values or as mean, standard deviation, and number of replicates. A sample MS Excel file is provided 3 .
Fig. 3: Overview of the different models to fit concentrationresponse data
A) The log-logistic 4-parameter model on which all fits are based. B) The three different fits (based on different parameter constraints) available to fit viability endpoint data. C) The three different fits (based on different parameter constraints) available to fit functional endpoint data. The green areas are based on the respective upper and lower parameter limits. They demonstrate the full range of curves that can be generated by the model. Conc, concentration selected for viability data) only to a small extent. The rationale was to rather tolerate a reduced fit quality at high concentrations than to accept the biologically rather implausible assumption that exactly 8% (number chosen only as example of an exact lower asymptote) of the cells will survive even the highest test concentrations.
A second case for which Fit 1 often works well is a weak, non-sigmoidal response, like a linear decrease, e.g., to 80% viability, at high test concentrations. However, users need to be careful with data that have a very gentle slope, as they are error-prone and uncertainties can be high. This is a typical case where users need to decide whether BMC determination is meaningful. Fit 2 and Fit 3 are suitable for sigmoidal responses with a lower asymptote that is clearly higher than 0%. An example case may be rel-during several years of experimental work with the fitting of real-life data sets (Nyffeler et al., 2017a,b) . Best results are obtained for low BMRs (e.g., 10-30%), as BMCeasy was mainly developed to determine the onset of toxicity. Accordingly, the program performance may be poor for BMRs > 50%.
For viability data (Fig. 3B) , Fit 1 works best for datasets with a steep concentration-response and a lower asymptote near 0%. The parameter setting takes into account the biological background that most viability data sets should theoretically approach 0% at high test concentrations. It also accounts for frequent experimental findings that there is sometimes an imperfect baseline correction or blank subtraction. Moreover, the parameter setting takes advantage of our experience that imperfect curve fits in the lower part of the curve affect BMCs with a low BMR (often BMR10 is
Fig. 4: Overview of data processing with the BMCeasy tool to determine the BMC and its confidence interval
The data are pre-processed manually before they are uploaded. Ideally, datasets from several independent experiments (BR, biological replicates) are used for input. Three different fits are available (➊➋➌; see also Fig. 3 ) to fit the concentration-response data. The program automatically identifies the most suitable concentration-response model and uses it to calculate the BMCs and the respective BMCL/BMCU. * at least three concentrations with a mean response exceeding the noise level. The noise level was defined as 5% for viability and 10% for the functional endpoint. logL, log-likelihood
Best model selection
Following principles of the Akaike information criterion 10 , concentration-response models were compared for their goodness of fit and for the risk of overfitting. Fit 2 and 3 have three degrees of freedom, while Fit 1 has only two degrees of freedom. Models with more degrees of freedom typically fit the data better, but they may also overfit them. Therefore, their use must be justified. The selection procedure was set in a way that Fit 1 is preferred over Fit 2 or 3 unless either of these models the data considerably better. Moreover, Fit 2 and Fit 3 can be selected only if there are at least three data points on the concentration-response ative cell count measurements for a cytostatic (but not cytotoxic) compound (Fig. 3B) . Fit 3 is intended to allow modelling of datasets with a lower asymptote > 80%.
For functional endpoints (Fig. 3C) , Fit 1 and 2 are similar to those for cytotoxicity data, while Fit 3 was included to account for datasets with upward concentration-response curves (Fig. 3C) . Notably, Fit 3 is not meant to generally capture all responses > 100% (e.g., motility, proliferation, reporter assays, etc.). It was included in the software to account for unexpected counter-regulations (e.g., cytostatic drugs that increase cell numbers; potential enzyme inhibitors that activate an enzyme, etc.). 10 https://www.statisticshowto.datasciencecentral.com/akaikes-information-criterion/
Fig. 5: Examples of reallife outputs from BMCeasy demonstrate how curves are fitted to various experimental datasets
A) Concentration-response data of mercury chloride from the PBEC-ALI assay (air-exposed primary bronchial epithelial cells). B) Percent of viable zebrafish embryos after 96 h exposure to valproic acid (VPA). C) Effect of hexachlorophene on migrating neural crest cells (cMINC assay). D) Concentration-response data of rotenone in peripheral neurons (PeriTox assay). E) Paclitaxel effects on the neurite area of peripheral neurons (PeriTox assay). F) Data of the NeuriTox assay using developing dopaminergic neurons (LUHMES cells). G) Fetal bovine serum (FBS) enhances cell migration of neural crest cells (cMINC). H) Cadmium chloride (CdCl2) inhibits neural crest cell migration (cMINC). G) and H) were adopted from Nyffeler et al. (2017b) . Data provided by the Leiden University Medical Center (LUMC), The Netherlands for panel A, by University of Heidelberg, Germany, for panel B, and by the University of Konstanz, Germany for panels C-H.
There are multiple options for layout and design of the graph (appearance of curves, legends, axes and data points). However, for users who prefer their own graphical representation, the parameters of the curve fit are returned. This allows reproduction in other programs.
BMCeasy has been used for processing the results of a broad variety of methods (Fig. 5) . Within the EU-ToxRisk project, its use spanned from air-exposed bronchial epithelial cells, through zebrafish embryos, neural crest cells and neurons to hepatocytes and kidney cell models. The example plots show that the tool can handle various challenges, such as curves with almost no decline ( Fig. 5A) , with large data uncertainty (Fig. 5B, C) , data with a lower asymptote > 0% (Fig. 5D, F) or curves with a very gentle decrease (Fig. 5E ) as well as data with increasing response ( Fig. 5G) .
Discussion and conclusion
We created a web-based tool to help experimental in vitro toxicologists without programming skills or extensive mathematical and statistical knowledge to calculate absolute BMC and BMCL values in a standardized way. As BMCeasy does not contain a quality check module for the input data, it requires the user to judge which types of data sets can be handled by the program and where problems may occur (Tab. 1). It is important to note that the program will to some extent also handle "non-suitable" data, and in such cases the delivered BMC data may not be meaningful. Like any research tool, the program has an applicability domain and a working environment that must be known and respected. For instance, non-monotonic responses or no-effect datasets cannot yield a reasonable BMC. Moreover, curve shapes that are very different from those obtained in typical cell-based assays potentially will not result in good quality estimates. The tool is not suitable for high-throughput efforts, as batch processing of multiple test compounds has not been implemented. A detailed manual 3 explains how to set up the analysis.
Currently, only the log-logistic curve is modelled. It has been suggested that a broad range of functions should be available for curve with a mean response exceeding the noise level. The noise levels were defined empirically as 5% for viability and 10% for the functional endpoint because these automatic settings worked well in practice. We set a higher noise level (10% instead of 5%) for functional endpoints because we observed that these types of endpoints often have higher variance than viability measurements. We consider fixed thresholds important to compare different experiments within a given assay and across different assays. A different strategy, i.e., a flexible noise level calculated from negative control data, has been chosen by others (Behl et al., 2019) . To decide between Fit 2 and Fit 3, their log-likelihood is determined (Fig. 4) .
BMC calculation
The best fits for viability or the functional endpoint are then used to derive the BMC and to calculate the respective BMCU and BMCL at the desired BMR.
To ensure that the estimated confidence interval is of best possible data quality, it is preferable that data from as many replicates as possible are included in the analysis; the number of concentrations tested as well as their spacing will also affect the output. For calculation of the CI, the ED function within the drc package (tlfs function pre-selected) is used (Ritz and Streibig, 2005) . The resulting CI is usually asymmetrical on a linear axis.
It is important to note that BMCeasy defines BMC as decline/ reduction of an absolute effect. For example, BMC 50 is a 50% reduction of the respective endpoint. For a curve with, e.g., an asymptote at 40%, this point does not coincide with the inflexion point of the curve (Fig. 2) . This feature differs from other modelling solutions (e.g., tcpl) (Filer et al., 2017) . According to the definition of the BMC underlying BMCeasy, an increase in response cannot be defined. This means that no BMC can be calculated if Fit 3 is selected for the functional endpoint.
Output
The calculated BMCs, BMCUs and BMCLs are returned in a table and can be downloaded as an Excel file. A graph with the concentration-response data of both endpoints and the respective best model fitting the data is plotted in publication quality. Ritz, 2010) . Even solutions for non-monotonic (e.g., hormesis) effects have been developed 11, 12 . A broad range of curve models is particularly important for high throughput data that are not manually controlled. The drc package used for BMCeasy has many curve models implemented, but we found that a limitation to the log-logistic function yields sufficiently good and more comparable results. Exceptions to this rule are possible and need to be excluded by visual control. The most severe limitation of BMCeasy is that it requires that datasets are normalized to 100% (for negative controls). A typical example of data that do not work is determining the percentage of lactate dehydrogenase (LDH) released from cells. In a typical assay, negative controls may show 15% release (spontaneous cell death) and positive controls 90% release. Such datasets may require complex transformation and renormalization (i.e., expressing data in terms of lactate dehydrogenase not released: 85% for negative controls, 10% for positive controls, then normalizing the negative control to 100% by dividing all data by 0.85).
Many test methods yield two endpoints, a viability/cytotoxicity endpoint and a functional endpoint (e.g., cell migration, electrical network activity, substrate transport or secretion of a biomolecule). Often the relation of the two endpoints is used to determine acceptance criteria or to identify hits. Therefore, it is often desired to represent them in one graph and to use the same tool for BMC calculations. BMCeasy is ideal for such cases. This allows experimenters, for example, to rapidly decide if the concentration spacing was chosen appropriately or if they should repeat their experiment with different compound dilutions.
